Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 65 points (-0.4%) at 16,380 as of Friday, Jan. 10, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,832 issues advancing vs. 1,123 declining with 123 unchanged. The Health Care sector currently sits up 0.4% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the sector include Biomarin Pharmaceutical ( BMRN), down 2.1%, Celgene Corporation ( CELG), down 2.1%, Amgen ( AMGN), down 2.0%, UnitedHealth Group ( UNH), down 1.8% and Humana ( HUM), down 1.6%. Top gainers within the sector include Intercept Pharmaceuticals ( ICPT), up 58.9%, Boston Scientific ( BSX), up 1.6%, AstraZeneca ( AZN), up 1.2% and Bristol-Myers Squibb Company ( BMY), up 0.9%. TheStreet would like to highlight 5 stocks pushing the sector lower today: 5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Care sector lower today. As of noon trading, DaVita HealthCare Partners is down $1.17 (-1.8%) to $64.47 on light volume. Thus far, 576,818 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $64.39-$65.85 after having opened the day at $65.85 as compared to the previous trading day's close of $65.64. DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $13.9 billion and is part of the health services industry. The company has a P/E ratio of 24.6, above the S&P 500 P/E ratio of 17.7. Shares are up 3.6% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.